Cargando…

Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts()

Human brain tumors such as glioblastomas are typically detected using conventional, nonquantitative magnetic resonance imaging (MRI) techniques, such as T2-weighted and contrast enhanced T1-weighted MRI. In this manuscript, we tested whether dynamic quantitative T1 mapping by MRI can localize orthot...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrmann, Kelsey, Erokwu, Bernadette O., Johansen, Mette L., Basilion, James P., Gulani, Vikas, Griswold, Mark A., Flask, Chris A., Brady-Kalnay, Susann M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833967/
https://www.ncbi.nlm.nih.gov/pubmed/27084431
http://dx.doi.org/10.1016/j.tranon.2016.02.004
_version_ 1782427420365684736
author Herrmann, Kelsey
Erokwu, Bernadette O.
Johansen, Mette L.
Basilion, James P.
Gulani, Vikas
Griswold, Mark A.
Flask, Chris A.
Brady-Kalnay, Susann M.
author_facet Herrmann, Kelsey
Erokwu, Bernadette O.
Johansen, Mette L.
Basilion, James P.
Gulani, Vikas
Griswold, Mark A.
Flask, Chris A.
Brady-Kalnay, Susann M.
author_sort Herrmann, Kelsey
collection PubMed
description Human brain tumors such as glioblastomas are typically detected using conventional, nonquantitative magnetic resonance imaging (MRI) techniques, such as T2-weighted and contrast enhanced T1-weighted MRI. In this manuscript, we tested whether dynamic quantitative T1 mapping by MRI can localize orthotopic glioma tumors in an objective manner. Quantitative T1 mapping was performed by MRI over multiple time points using the conventional contrast agent Optimark. We compared signal differences to determine the gadolinium concentration in tissues over time. The T1 parametric maps made it easy to identify the regions of contrast enhancement and thus tumor location. Doubling the typical human dose of contrast agent resulted in a clearer demarcation of these tumors. Therefore, T1 mapping of brain tumors is gadolinium dose dependent and improves detection of tumors by MRI. The use of T1 maps provides a quantitative means to evaluate tumor detection by gadolinium-based contrast agents over time. This dynamic quantitative T1 mapping technique will also enable future quantitative evaluation of various targeted MRI contrast agents.
format Online
Article
Text
id pubmed-4833967
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-48339672016-04-27 Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts() Herrmann, Kelsey Erokwu, Bernadette O. Johansen, Mette L. Basilion, James P. Gulani, Vikas Griswold, Mark A. Flask, Chris A. Brady-Kalnay, Susann M. Transl Oncol Original article Human brain tumors such as glioblastomas are typically detected using conventional, nonquantitative magnetic resonance imaging (MRI) techniques, such as T2-weighted and contrast enhanced T1-weighted MRI. In this manuscript, we tested whether dynamic quantitative T1 mapping by MRI can localize orthotopic glioma tumors in an objective manner. Quantitative T1 mapping was performed by MRI over multiple time points using the conventional contrast agent Optimark. We compared signal differences to determine the gadolinium concentration in tissues over time. The T1 parametric maps made it easy to identify the regions of contrast enhancement and thus tumor location. Doubling the typical human dose of contrast agent resulted in a clearer demarcation of these tumors. Therefore, T1 mapping of brain tumors is gadolinium dose dependent and improves detection of tumors by MRI. The use of T1 maps provides a quantitative means to evaluate tumor detection by gadolinium-based contrast agents over time. This dynamic quantitative T1 mapping technique will also enable future quantitative evaluation of various targeted MRI contrast agents. Neoplasia Press 2016-04-12 /pmc/articles/PMC4833967/ /pubmed/27084431 http://dx.doi.org/10.1016/j.tranon.2016.02.004 Text en © 2016 Pfizer Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Herrmann, Kelsey
Erokwu, Bernadette O.
Johansen, Mette L.
Basilion, James P.
Gulani, Vikas
Griswold, Mark A.
Flask, Chris A.
Brady-Kalnay, Susann M.
Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts()
title Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts()
title_full Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts()
title_fullStr Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts()
title_full_unstemmed Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts()
title_short Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts()
title_sort dynamic quantitative t1 mapping in orthotopic brain tumor xenografts()
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833967/
https://www.ncbi.nlm.nih.gov/pubmed/27084431
http://dx.doi.org/10.1016/j.tranon.2016.02.004
work_keys_str_mv AT herrmannkelsey dynamicquantitativet1mappinginorthotopicbraintumorxenografts
AT erokwubernadetteo dynamicquantitativet1mappinginorthotopicbraintumorxenografts
AT johansenmettel dynamicquantitativet1mappinginorthotopicbraintumorxenografts
AT basilionjamesp dynamicquantitativet1mappinginorthotopicbraintumorxenografts
AT gulanivikas dynamicquantitativet1mappinginorthotopicbraintumorxenografts
AT griswoldmarka dynamicquantitativet1mappinginorthotopicbraintumorxenografts
AT flaskchrisa dynamicquantitativet1mappinginorthotopicbraintumorxenografts
AT bradykalnaysusannm dynamicquantitativet1mappinginorthotopicbraintumorxenografts